Efficacy of TRKi–Larotrectinib Among Tumor Types

David Hong, MD, and Corey Langer, MD, discuss updated data presented at ASCO 2019 Annual Meeting and results of the clinical trials and efficacy of larotrectinib among tumor types. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/